En undersøgelse af Orelabrutinib hos patienter med sekundær progressiv multipel sklerose
En fase 3, randomiseret, dobbeltblind effektivitets- og sikkerhedsundersøgelse, der sammenligner Orelabrutinib med placebo hos patienter med ikke-aktiv sekundær progressiv multipel sklerose
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
The study consists of the following periods:
- Screening Period: Up to 4 weeks.
- Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
- Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
- Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
- Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).
All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Patient and Medical Information
- Telefonnummer: 833-269-4696
- E-mail: clinicaltrialsinfo@zenasbio.com
Undersøgelse Kontakt Backup
- Navn: Patient and Medical Information
- Telefonnummer: 833-269-4696
- E-mail: clinialtrialsinfo@zenasbio.com
Studiesteder
-
-
New South Wales
-
Kogarah, New South Wales, Australien, 2217
- Rekruttering
- Southern Neurology Suite 2
-
-
-
-
-
Sovet, Belgien, 1408
- Rekruttering
- DCC Neoclinic - Sofia
-
-
Limburg
-
Overpelt, Limburg, Belgien, 3900
- Rekruttering
- MS-Netwerk Limburg - Revalidatie
-
-
-
-
-
Pleven, Bulgarien, 5800
- Rekruttering
- Avis Medica Hospital Pleven
-
-
Plovdiv
-
Plovdiv, Plovdiv, Bulgarien, 4000
- Rekruttering
- Medical Center Nevrocentrum
-
-
Sofia
-
Sofia, Sofia, Bulgarien, 1680
- Rekruttering
- Diagnostic and Consultative Center Convex
-
Sofia, Sofia, Bulgarien, 1510
- Rekruttering
- Medical Center Hera EOOD
-
-
Tarnovo
-
Veliko Tarnovo, Tarnovo, Bulgarien, 5000
- Rekruttering
- Medical Center Medica Plus OOD
-
-
-
-
Harju
-
Tallinn, Harju, Estland, 10617
- Rekruttering
- Astra clinic (Clinic4U)
-
-
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85032
- Rekruttering
- Arizona Neuroscience Research, LLC
-
Scottsdale, Arizona, Forenede Stater, 85253
- Rekruttering
- Perseverance Research Center, LLC (PRC)
-
-
California
-
Fullerton, California, Forenede Stater, 92835
- Rekruttering
- Fullerton Neurology and Headache Center
-
Torrance, California, Forenede Stater, 90502-2006
- Rekruttering
- Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
-
West Hollywood, California, Forenede Stater, 90048
- Rekruttering
- Regina Berkovich MD, PhD Inc
-
-
Florida
-
Boca Raton, Florida, Forenede Stater, 33487
- Rekruttering
- SFM Clinical Research, LLC
-
Bradenton, Florida, Forenede Stater, 34209
- Rekruttering
- Nova Clinical Research, LLC
-
Clearwater, Florida, Forenede Stater, 33761
- Rekruttering
- MS and Neuromuscular Center of Excellence
-
Maitland, Florida, Forenede Stater, 32751
- Rekruttering
- Neurology Associates
-
Naples, Florida, Forenede Stater, 34105
- Rekruttering
- Aqualane Clinical Research
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- University of South Florida Department of Neurology - MS Division
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46256
- Rekruttering
- Josephson Wallack Munshower Neurology, Pc Suite 225
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Rekruttering
- University of Kansas Medical Center
-
Roeland Park, Kansas, Forenede Stater, 66205
- Rekruttering
- KC Research Center, PA Neurology Research Dept
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02131
- Trukket tilbage
- Boston Clinical Trials
-
Worcester, Massachusetts, Forenede Stater, 01655
- Rekruttering
- University of Massachusetts Memorial Medical Center
-
-
Michigan
-
Rochester Hills, Michigan, Forenede Stater, 48307
- Rekruttering
- Profound Research LLC at Oakland Neurology Center
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Rekruttering
- Washington University School of Medicine
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87131
- Rekruttering
- University Of New Mexico School Of Medicine
-
-
New York
-
New York, New York, Forenede Stater, 10029
- Rekruttering
- Mount Sinai Medical Center
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43235
- Rekruttering
- The Boster Center for Multiple Sclerosis
-
Columbus, Ohio, Forenede Stater, 43221
- Rekruttering
- The Ohio State University Wexner Medical Center (OSUWMC)
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- Rekruttering
- OMRF Multiple Sclerosis Center of Excellence
-
-
South Carolina
-
Greenville, South Carolina, Forenede Stater, 29605
- Rekruttering
- Premier Neurology
-
-
Tennessee
-
Cordova, Tennessee, Forenede Stater, 38018
- Rekruttering
- Neurology Clinic, P.C.
-
-
Texas
-
San Antonio, Texas, Forenede Stater, 78258
- Rekruttering
- Lone Star Neurology
-
Sherman, Texas, Forenede Stater, 75092
- Rekruttering
- Texas Institute for Neurological Disorders - Sherman
-
-
-
-
Brest
-
Pordic, Brest, Frankrig, 29609
- Rekruttering
- CHU Brest Hospital Cavale
-
-
Gard
-
Nîmes, Gard, Frankrig, 30029
- Rekruttering
- Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
-
-
Yveline
-
Poissy, Yveline, Frankrig, 78300
- Rekruttering
- Centre Hospitalier Intercommunal (Chi) Poissy-Saint-Germain-En-Laye - Site De Poissy
-
-
-
-
-
Tbilisi, Georgien, 0114
- Rekruttering
- LTD Pineo Medical Ecosystem
-
Tbilisi, Georgien, 0186
- Rekruttering
- Raymann, LLC
-
Tbilisi, Georgien, 0159
- Rekruttering
- NNLE Jo Ann University Hospital
-
Tbilisi, Georgien, 0186
- Rekruttering
- Caucasus Medical Center Ltd
-
-
K'alak'i T'bilisi
-
Tbilisi, K'alak'i T'bilisi, Georgien, 0114
- Rekruttering
- JSC Curatio
-
-
Saburtalo
-
Tbilisi, Saburtalo, Georgien, 0160
- Rekruttering
- MD Georgia Staff Physician MediClub Georgia
-
-
-
-
Athens
-
Cholargós, Athens, Grækenland, 15562
- Rekruttering
- Metropolitan General Hospital
-
-
Attica
-
Athens, Attica, Grækenland, 11526
- Rekruttering
- Errikos Dunant Hospital
-
-
-
-
Chieti
-
Chieti, Chieti, Italien, 66100
- Rekruttering
- University G. D'Annunzio of Chieti-Pescara
-
-
Isernia/Molise
-
Pozzilli, Isernia/Molise, Italien, 86077
- Rekruttering
- IRCCS Istituto Neurologico Mediterraneo Neuromed
-
-
-
-
-
Zagreb, Kroatien, 10 000
- Rekruttering
- Klinicki Bolnicki Centar Zagreb-Rebro
-
-
-
-
Kauno
-
Kaunas, Kauno, Litauen, 50161
- Rekruttering
- Hospital of Lithuanian University of Health Sciences
-
-
-
-
-
Lublin, Polen, 20-064
- Rekruttering
- Galen Clinic
-
Plewiska, Polen, 62-064
- Rekruttering
- Neurologiczny Niepubliczny ZOZ Centrum Leczenia SM Osrodek Badan Klinicznych im. dr n. med. Hanki Hertmanowskiej
-
Poznan, Polen, 15-540
- Rekruttering
- Prywatna Lecznica Certus Sp. z o.o.
-
Szczecin, Polen, 70-111
- Rekruttering
- EUROMEDIS Osrodek Badan Klinicznych
-
Żory, Polen, 44-240
- Rekruttering
- Centrum Medyczne ProNeuro Żory
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Polen, 85-605
- Rekruttering
- Centrum Medyczne INTERCOR Sp. z o.o.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-601
- Rekruttering
- Malva Trials
-
Lublin, Lublin Voivodeship, Polen, 20-064
- Rekruttering
- Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
-
Lublin, Lublin Voivodeship, Polen, 20-064
- Rekruttering
- NZOZ Neuromed M. i M. Nastaj Sp.P
-
-
Lubusz Voivodeship
-
Nowa Sól, Lubusz Voivodeship, Polen, 67-100
- Rekruttering
- Twoja Przychodnia Centrum Medyczne Nowa Sól
-
-
Mazovian
-
Warsaw, Mazovian, Polen, 02-172
- Rekruttering
- MTZ Clinical Researcz Powered by pratia
-
-
Rzeszów
-
Rzeszów, Rzeszów, Polen, 35-323
- Rekruttering
- Nmedis sp. z o.o.
-
-
Silesian Voivodeship
-
Katowice, Silesian Voivodeship, Polen, 40-081
- Rekruttering
- Centrum Medyczne Pratia Katowice
-
Katowice, Silesian Voivodeship, Polen, 40-571
- Rekruttering
- MA-LEK Clinical Sp. z o.o.
-
Katowice, Silesian Voivodeship, Polen, 40-584
- Rekruttering
- NZOZ Novo Med
-
-
Upper Silesia
-
Katowice, Upper Silesia, Polen, 40-686
- Rekruttering
- Neuro Medic Clinic
-
-
Wielkopolska
-
Poznan, Wielkopolska, Polen, 61-853
- Rekruttering
- Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
-
Poznan, Wielkopolska, Polen, 60-324
- Rekruttering
- Twoja Przychodnia PCM
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polen, 91-743
- Rekruttering
- PRO SALUS Sp. z o.o. sp.k.
-
Lodz, Łódź Voivodeship, Polen, 90-324
- Rekruttering
- Centrum Neurologii Krzysztof Selmaj
-
-
-
-
-
Guaynabo, Puerto Rico, 00969
- Rekruttering
- Caribbean Center for Clinical Research
-
-
-
-
Constanța County
-
Constanța, Constanța County, Rumænien, 900123
- Rekruttering
- Spital Clinic CF Constanta
-
-
Suceava
-
Radauti, Suceava, Rumænien, 725400
- Rekruttering
- Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
-
-
-
-
-
Kragujevac, Serbien, 34000
- Rekruttering
- University Clinical Centre of Kragujevac
-
Niš, Serbien, 18000
- Rekruttering
- Clinic of Neurology - Clinical Center Nis
-
-
Belgrade
-
Belgrade, Belgrade, Serbien, 11000
- Rekruttering
- University Clinical Centre of Serbia
-
-
-
-
A Coruña
-
A Coruña, A Coruña, Spanien, 15006
- Rekruttering
- Complejo Hospitalario Universitario A Coruña
-
-
Galicia
-
Vigo, Galicia, Spanien, 36312
- Rekruttering
- Hospital Alvaro Cunqueiro
-
-
Madrid
-
Madrid, Madrid, Spanien, 28007
- Rekruttering
- Hospital Gregorio Marañon
-
Majadahonda, Madrid, Spanien, 28222
- Rekruttering
- Hospital Universitario Puerta de Hierro de Majadahonda
-
-
Málaga
-
Málaga, Málaga, Spanien, 29016
- Rekruttering
- Vithas Hospital Parque San Antonio
-
-
Seville
-
Castilleja de la Cuesta, Seville, Spanien, 41950
- Rekruttering
- Hospital Vithas Nisa Sevilla
-
-
-
-
-
Choceň, Tjekkiet, 56501
- Rekruttering
- NEUROHK, s.r.o.
-
Jihlava, Tjekkiet, 58601
- Rekruttering
- Regional Hospital Jihlava
-
-
-
-
Hesse
-
Bad Homburg, Hesse, Tyskland, 61348
- Rekruttering
- Zentrum fur klinische Forschung Dr.Scholl GmbH
-
-
-
-
-
Ivano-Frankivsk, Ukraine, 76943
- Rekruttering
- Neuro Global
-
Lviv, Ukraine, 79010
- Rekruttering
- Lviv National Medical University named after Danylo Galytskiy
-
Vinnytsia, Ukraine, 21009
- Rekruttering
- Medical Clinical Investigational Center of Medical Center LLC Health Clinic
-
-
Chernivtsi Oblast
-
Chernivtsi, Chernivtsi Oblast, Ukraine, 58023
- Rekruttering
- Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
-
-
Ivano-Frankivs'k Oblast
-
Ivano-Frankivsk, Ivano-Frankivs'k Oblast, Ukraine, 76018
- Rekruttering
- CNE City Clinical Hospital #1 of Ivano-Frankivsk council
-
-
Lviv Oblast
-
Lviv, Lviv Oblast, Ukraine, 79000
- Rekruttering
- Limited Liability Company Medical Center Neuroclinic
-
Lviv, Lviv Oblast, Ukraine, 79029
- Rekruttering
- Limited Liability Company "Neurofocus"
-
-
-
-
-
Budapest, Ungarn, 1145
- Rekruttering
- National Institute of Clinical Neurosciences
-
Tatabánya, Ungarn, 2800
- Rekruttering
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz
-
-
Komarom-Esztergom Vamegye
-
Esztergom, Komarom-Esztergom Vamegye, Ungarn, 2500
- Rekruttering
- Valeomed Kft.
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- 18 to 60 years of age, inclusive, at the time of signing the informed consent.
- Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
- Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
- Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
- Absence of clinical relapses for at least 24 months.
Exclusion Criteria:
- The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
- Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
- History or current diagnosis of other neurological disorders that may mimic MS
- History or current diagnosis of progressive multifocal leukoencephalopathy
- Active, clinically significant viral, bacterial, or fungal infection
- History of any other significant active medical condition
- History of suicidal behavior within 6 months prior to Screening
- Any prior history of malignancy
- Patients on anticoagulation, or antiplatelet therapy
- Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
- Clinically significant laboratory abnormalities at Screening.
- Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
- History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Orelabrutinib Group
Orelabrutinib PO daily |
Orelabrutinib orally |
|
Placebo komparator: Placebo Group
Placebo PO daily |
Placebo orally |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
Tidsramme: Up to approximately 120 weeks
|
Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0 |
Up to approximately 120 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
12 Week CDP
Tidsramme: Up to approximately 120 weeks
|
Time to onset of CDP events on EDSS, confirmed over at least 12 weeks |
Up to approximately 120 weeks
|
|
T2 lesions on MRI
Tidsramme: Up to approximately 120 weeks
|
The total number of new or enlarging T2 lesions on MRI scans of the brain |
Up to approximately 120 weeks
|
|
24-week CDP-9-hole Peg Test
Tidsramme: Up to approximately 120 weeks
|
Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDP-T25FWT
Tidsramme: Up to approximately 120 weeks
|
Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI
Tidsramme: Up to approximately 120 weeks
|
Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-9HPT
Tidsramme: Up to approximately 120 weeks
|
Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-T25FWT
Tidsramme: Up to approximately 120 weeks
|
Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
Symbol Digit Modalities Test
Tidsramme: Up to approximately 120 weeks
|
The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit |
Up to approximately 120 weeks
|
|
Annualized relapse rate
Tidsramme: Up to approximately 120 weeks
|
Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses |
Up to approximately 120 weeks
|
|
To evaluate the safety and tolerability of orelabrutinib
Tidsramme: Up to approximately 120 weeks
|
Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0); |
Up to approximately 120 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i nervesystemet
- Patologiske processer
- Kronisk sygdom
- Sygdomsegenskaber
- Autoimmune sygdomme
- Sygdomme i immunsystemet
- Demyeliniserende autoimmune sygdomme, CNS
- Autoimmune sygdomme i nervesystemet
- Demyeliniserende sygdomme
- Patologiske tilstande, tegn og symptomer
- Multipel sclerose
- Multipel sklerose, kronisk progressiv
- Orelabrutinib
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ZB020-03-002
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .